On April 25, 2024 Compugen Ltd. (NASDAQ: CGEN) (TASE:CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, reported that it will present new clinical data on COM701 (anti-PVRIG) in triple combination with COM902 (anti-TIGIT) and pembrolizumab in microsatellite stable colorectal cancer at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting on May31-June 4 2023, in Chicago, Illinois (Press release, Compugen, APR 25, 2024, View Source [SID1234642366]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Presentation Details:
Title: Preliminary antitumor activity of COM701 in combination with COM902 and pembrolizumab in patients with MSS-CRC and liver metastases
Abstract Number: 3597
Session Title: Gastrointestinal Cancer – Colorectal and Anal
Lead Author: Dr. Manish Sharma
Date: Saturday, June 1, 2024; 1:30PM-4:30PM CDT